The renin-angiotensin system (RAS) is a strong candidate as a mediator for the development and progression of lupus nephritis (LN). We performed an ethnically stratified analysis of 642 systemic lupus erythematosus (SLE) patients to determine whether various functional RAS gene polymorphisms are associated with SLE renal outcomes. Patients were genotyped for two angiotensin-converting enzyme (ACE) gene polymorphisms: Alu insertion/deletion (I/D) and 23 949 (CT) 2/3 , and for two angiotensinogen (Atg) gene polymorphisms: M235T and C-532T. Multivariate analyses demonstrated associations between the ACE I/D, ACE (CT) 2/3 and Atg C-532T functional polymorphisms and LN among Asians. In stratified analyses among LN cases according to high vs low glomerular filtration rate (GFR), associations remained significant for the ACE D (odds ratio (OR) 5.9, P ¼ 0.001) and (CT) 2 (OR 6.2, P ¼ 0.001) alleles among Asian subjects with low GFR. Lastly, we found allelic dosedependent associations between the ACE I/D (P ¼ 0.003), ACE (CT) 2/3 (P ¼ 0.005) and Atg M235T (P ¼ 0.04) polymorphisms, and GFR analyzed as a continuous variable among Asians. These findings suggest a significant role for ACE and Atg gene sequence variation and severity of LN among Asians with SLE.
Introduction
Lupus nephritis (LN) is common and considered the foremost cause of the increased morbidity and mortality associated with systemic lupus erythematosus (SLE). 1 Both SLE and end-stage renal disease (ESRD) show clear familial patterns, suggesting a significant genetic component to disease development and/or progression. [2] [3] [4] There is also evidence based on both animal models and humans implicating a set of LN and end organ damage susceptibility genes distinct from those that influence general SLE susceptibility. 5, 6 Angiotensin-II, the main effector molecule of the renin-angiotensin system (RAS), is a pleiotropic molecule that can function as a vasoactive peptide and growth factor contributing to tissue remodeling and fibrosis. 7, 8 Angiotensin-II is also a potent proinflammatory modulator with the ability to augment and perpetuate immune responses in renal and nonrenal tissues. 9, 10 The precursor angiotensinogen (Atg) protein is proteolytically processed by renin to yield angiotensin-1. Angiotensin-1 is subsequently converted to the biologically active angiotensin-II peptide by angiotensinconverting enzyme (ACE). Angiotensin-II binds to several receptors augmenting both the inflammatory and fibrotic pathways, leading to the progression of disease. Increases in renal glomerular and tubular mRNA production of ACE, Atg and renin have been demonstrated in LN, 11 and pharmacological blockade of the RAS has consistently been shown to significantly decrease the progression of all proteinuric renal diseases. 12, 13 Previously, using a family-based transmission-disequilibrium test (TDT) design in the same population, we found an association between ACE gene sequence variations and both SLE and LN among non-Caucasians. 14 In view of our previous findings and known pathophysiologic effects of angiotensin-II, we hypothesized that functional gene polymorphisms related to the production of angiotensin-II may be associated with the progression of renal disease in patients with LN. For the current study, we examined two ACE polymorphisms, Alu insertion/deletion (I/D) (involving a 287 base pair (bp) sequence of DNA in intron 16) and (CT) 2/3 (2 vs 3 CT dinucleotides in the 3 0 -untranslated region) for association with LN and progression of renal disease in a large multiethnic SLE cohort. The D allele is known to correlate with increased tissue 15 and serum ACE levels in a dose-dependent manner in various ethnic groups. [16] [17] [18] [19] The (CT) 2 polymorphism was shown to correlate with serum ACE in French and Nigerian populations. 16, 19 We also examined two Atg polymorphisms, M235T (C to T transition at position 4072) and C-532T (C to T transition in 5 0 -flanking region). The M235T T allele is correlated in an allelic dose-dependent manner with Atg tissue levels 20 and with increased serum levels in various ethnic groups. [21] [22] [23] The Atg À532T allele was shown in one study to correlate with increased serum Atg levels. 16 
Results
Demographic and clinical characteristics of SLE patients differed significantly between the LN and non-LN subgroups ( Table 1) . As a group, the LN patients were more likely to be male and to be non-Caucasian. They also developed SLE at an earlier age and had a longer duration of disease. Among subjects with LN, 31% had ESRD, contributing to a total of 54% with a glomerular filtration rate (GFR) o60 ml/min/1.73 m 2 . Also, 71% of the LN subjects had received at least 6 months of cytotoxic treatment. Selected characteristics of LN subjects are shown in Table 2 .
Primary analyses
All analyses were stratified based on ethnicity. The ethnic subgroups consisted of Caucasians (n ¼ 391), Asians (ie from East Asia, n ¼ 96), Hispanics (n ¼ 92) and African Americans (n ¼ 63). We tested for deviation from HardyWeinberg equilibrium (HWE) in all ethnic control groups (SLE without LN) and found significant deviations for all polymorphisms among Hispanic controls. This suggested either a heterogeneous population or significant selection bias; hence, we excluded this subgroup from further analysis. All other ethnic control groups were in HWE.
Linkage disequilibrium (LD) was calculated for the C-532T and M235T Atg markers. Lewontin's D 0 coefficients in Caucasians, African Americans and Asians were 0.144, 0.487, and 0.307, respectively, demonstrating no major LD. The ACE I/D and (CT) 2/3 polymorphisms were in strong LD with D 0 coefficients of 0.924, 0.870 and 0.933 in Caucasians, African Americans and Asians, respectively.
We first looked for associations based on allele and genotype distributions with the presence of LN. The ACE I/D, ACE (CT) 2/3 and Atg C-532T markers were associated with LN among Asians. Since we had hypothesized that RAS genotype may be more specifically associated with the progression as opposed to the development of LN, we stratified the LN cases according to GFR (low vs high). Genotype and allele frequencies for LN patients with high GFR were similar to non-LN SLE controls (data not shown). However, we observed significant genotype and allele associations among Asian LN cases with low GFR as displayed in Tables 3-6 .
Next, we used a logistic regression model to adjust for baseline differences in disease duration and age of onset. The small number of male subjects did not always allow for adjustment by gender for ethnic subgroups in the logistic model (eg no Asian LN male with M235 C allele and low GFR). When feasible, the inclusion of gender did not significantly affect the results. Renal disease and GFR significantly affect blood pressure, and high blood pressure is on the causal pathway for progressive loss of GFR. Therefore, blood pressure was not considered as an independent variable and was not included in the multivariate models. Consistent with the univariate results in the logistic regression model, significant associations were observed only for the Asian subgroup, as shown in Table 7 (other ethnic group data not shown).
We also examined genetic associations with GFR as a continuous variable. Using a linear regression model to adjust for effects due to age, gender, disease duration and cytotoxic treatment, we found evidence of allelic dosedependent effects of the ACE (CT) 2 , D and Atg 235T alleles with GFR in Asians (Figure 1 ), which are consistent with the allelic dose-dependent effect of these functional polymorphisms. [16] [17] [18] [19] [20] [21] [22] [23] For the Atg C-532T 
Secondary analyses
Since our results were markedly specific to the Asian subgroup, we looked for potential biases in the various ethnic subgroups. First, we examined for departures . Given that our non-LN SLE patients were in HWE, these deviations among LN cases suggest a non-steady-state population, possibly explained by genotype-related survival bias among LN cases. Furthermore, since our Asian subgroup consisted of subjects with different countries of ancestral origin within East Asia, we looked for evidence of heterogeneity in this population. Thus, we examined three Asian subgroups, Chinese (n ¼ 38), Filipino (n ¼ 24) and other East Asians (n ¼ 34). We did not find any significant differences in LN prevalence or genotype distribution among these subpopulations. Nonetheless, since the small number of subjects in each subgroup limited our power to detect significant differences, we also examined each subgroup for genotypic associations with low GFR and found consistent positive odds ratios for all four polymorphisms in all three Asian subgroups (data not shown).
Lastly, we tested for additive effects of the various polymorphisms by including all four markers in the same logistic model, along with age at diagnosis and disease duration. Again, solely in the Asian low GFR subgroup, we found evidence of additive effects between the ACE D, (CT) 2 and Atg -532T risk alleles. We then looked for joint effects of all two-marker combinations and observed associations among the low GFR (Table 8) but not high GFR groups.
Discussion
Considering that the initial development of LN by the American College of Rheumatology (ACR) renal criteria may lack specificity for the progression of LN and ESRD, we have focused our attention on genetic pathways for the progression of renal insufficiency, and hence severity of LN-associated renal outcomes. The RAS is a strong candidate as prior studies have demonstrated a more consistent association between ACE and Atg gene variants with the progression of renal insufficiency in various renal diseases, compared to the initiation of renal inflammation. [24] [25] [26] [27] The results of this study suggest that DNA sequence variation in the ACE and Atg genes significantly influences the rate of progression of renal disease, and potentially survival, in LN patients. Previous studies in LN have been limited to the ACE I/D polymorphism, and have yielded highly discordant results. 14, [28] [29] [30] [31] [32] [33] [34] One of the larger studies with 144 LN cases in a Chinese population demonstrated an increase in the ACE D allele in LN compared to healthy controls and, similar to our study, further increase of the D allele was observed in LN patients with progressive renal insufficiency compared to patients with stable LN. 28 In a study of Korean patients (83 with LN), no association with LN was found. 29 However, the average disease duration in that cohort was 2.9 years, which would limit the ability to 2 , and Atg 235T) with GFR and were calculated using a linear regression model to adjust for age, gender, disease duration and cytotoxic treatment.
RAS gene polymorphisms and lupus nephritis
A Parsa et al classify patients into progressive and nonprogressive renal disease. Another study of 84 Japanese SLE cases reported an unexpected association between LN and the ACE I allele. 30 However, this population was unusual since it was an incident cohort of SLE patients in whom serial biopsies were performed, even in the absence of clinical LN. In biopsy studies, because of the high frequency of subclinical evidence of LN (immune complex deposition with minimal mesangial proliferation), over 90% of patients have been diagnosed with LN. 35 Furthermore, the disease duration in these patients was less than 1 year, which would not allow for proper classification of renal status. Finally, this study did not examine association with renal insufficiency, which was the outcome that fully accounted for our positive findings.
Studies in non-Asian ethnic subgroups have also been difficult to interpret. In a study that included 78 African-American SLE patients, no significant association between the D allele or DD genotype and LN or GFR was observed. 31 However, despite shorter disease duration in the DD vs II patients with LN, consistent with our findings, the DD patients had lower mean GFR (73 vs 91 among II patients). In a linkage analysis of the ACE I/D in SLE, although no significant association with SLE was observed, the LOD score did increase in the Caucasian LN subgroup, and a significant increase in the DD genotype was observed in the African-American LN subgroup. 32 A study of Croatian SLE patients (34 with LN) 33 and an Israeli study of SLE patients (24 with LN) did not find an association of the D allele with LN. 34 Careful review of these previous studies in SLE suggests that much of the discordance may be secondary to heterogeneous study designs, power, disease state, phenotype definition and ethnic variability. Of interest, three studies that used a measure of renal insufficiency and/or non-LN SLE controls, analogous to our study, found significant or suggestive associations of the ACE D allele with LN or decreased GFR in LN. 28, 31, 32 We are not aware of any previous studies that have analyzed Atg variants in LN or SLE.
Our results also demonstrate ethnic differences in these genetic associations. Several factors may account for this, including low power in specific ethnic strata, variable genetic effects based on ethnicity and variable selection bias. True ethnic heterogeneity certainly may account for some of this variation. Indeed, ethnic variability in LN prevalence and severity has been noted. 36, 37 Furthermore, several studies and metaanalyses of ACE and Atg polymorphisms demonstrate significant ethnic heterogeneity, with stronger associations of the D allele or DD genotype in Asian compared to Caucasian populations. 17, 18, 38 It is also possible given the retrospective study design that there may have been some selection bias due to decreased survival in patients with genotypes associated with higher RAS activity. This has been previously suggested in both a predialysis and dialysis population. 39, 40 In our study, we found highly significant deviation from HWE for the Atg M235T variant among Caucasians and Asians with low GFR, and for the ACE I/D polymorphism among African Americans with low GFR. Departures from HWE may indicate genotype-based differential survival, genotype error, nonrandom mating and/or population stratification. 41 Since deviations from HWE in these ethnic subgroups were specific to the cases (ie non-LN SLE controls were in HWE), the most likely explanation is genotype-related survival bias among patients with LN and low GFR, rather than genotyping error or nonrandom mating confined to the low GFR group. We also found additive effects of the ACE D, (CT) 2 and Atg À532T alleles in our Asian subgroup. Similarly, in a previous TDT analysis, we observed strong association between the ACE D-(CT) 2 haplotype and a nonCaucasian LN subgroup.
14 These findings further support the potential significance of overall RAS activity to LN outcomes.
There are several limitations to the current study. First, although the total number of patients examined was large, the smaller size of individual non-Caucasian subgroups limited the analytic power. Second, the two ACE and two Atg polymorphisms examined do not represent comprehensive coverage of these genes, thus it is possible that examination of additional markers and subsequent analysis of haplotypes would have revealed different or more striking association with disease. Some studies have shown significant ethnic variability in haplotypes in both ACE and Atg genes, in addition to better correlation between four-marker-based haplotypes and gene function compared to single polymorphisms for both ACE and Atg genes.
23,42
Although we did not measure serum or tissue ACE and Atg levels in these patients, previous studies have documented strong associations between serum and tissue levels of ACE I/D in various ethnic populations. [16] [17] [18] [19] The (CT) 2/3 marker was also shown to be associated with serum levels of ACE and demonstrated independent and additive association with the ACE I/D polymorphism and LN in the current study and a previous TDT analysis. 14 However, the role of the Atg C-532T variant remains unclear. Two studies found the À532T allele to be in strong LD with 235T, which was associated with elevated Atg levels. 22, 43 Conversely, no strong LD was noted in the current and another study. 23 Interestingly, our results suggest phenotype correlation between the Atg 235T and À532C alleles, which is in contrast to the LD findings in some of the other studies. 22, 43 Considering the marked variability in these studies, the effect of the C-532T polymorphism on Atg production in various populations remains to be defined.
Lastly, with three ethnic groups and three nonlinked markers our results may represent false positive associations. However, these markers are not fully independent since they are functionally related to the same pathophysiologic pathway (RAS). Moreover, the LN-and GFRrelated outcomes are also not independent. The issue of statistical correction for multiple testing, notably in the context of investigative studies, is subject to much debate. 44, 45 It is argued that replication of findings and biologic plausibility may be a better way to minimize false-positive results. The biologic plausibility of our findings is supported by the known functions of the RAS and the observed dose-response associations with GFR, which correlates with the allelic dose-dependent activity of the known functional polymorphisms. Additionally, considering the magnitude of effect (eg ACE D allele, adjusted odds ratio (OR) 5.9, P ¼ 0.001), it would be improbable for population admixture or an unknown confounder to fully account for the observed associations. Finally, despite the highly significant variation in previous studies of the ACE D allele, the three studies most similar to ours (focusing on progression and/or using SLE subjects without LN as controls) yielded results consistent with our findings. 28, 31, 32 In conclusion, we found significant genetic associations of two chromosomally independent RAS genes with the specific phenotype of progressive LN. Our results demonstrate strong associations of two ACE variants with low GFR among Asian LN patients. We also found allelic dose-dependent associations between two ACE and one Atg polymorphisms with GFR. Specific HWE deviations suggest a potential survival effect of the ACE I/D and Atg M235T genotypes. Lastly, additive effects between the two ACE and the Atg C-532T markers and low GFR were noted. Together, these findings support an important role of individual and joint ACE and Atg gene sequence variations, and hence the RAS, in the pathophysiology of LNrelated outcomes. In view of the ethnic specificity of the results, deviations from HWE among cases, retrospective design and the relatively small numbers of patients available for the analysis of specific subgroups, additional studies will be required to confirm and extend these findings. These studies should preferably be prospective in nature, include larger numbers of subjects from specific ethnic subgroups, and additional polymorphisms in the region to facilitate haplotype analyses.
Materials and methods

Subjects
We studied a total of 642 SLE patients. Informed consent was obtained from all patients and the study was approved by the institutional review board at the University of California, San Francisco (UCSF). Study subjects were participants in the UCSF Lupus Genetics Project and were recruited from UCSF Arthritis Clinics, private rheumatology practices in Northern California and nationwide outreach. All patients fulfilled the ACR revised criteria for SLE. 46, 47 Ethnic background was determined based on the ancestries of each subject's four grandparents.
LN classification
Patients were classified as LN if they met the ACR renal criteria and/or if they had renal biopsy evidence of LN (ie immune complex deposition). The ACR renal criteria require evidence of persistent proteinuria (ie 40.5 g/24 h or þ 3 if urine dipstick only) or 'active sediment' (ie cellular casts-red cell, granular, tubular or mixed). Patients with other specific predisposing causes for renal disease such as diabetes or liver failure were excluded from the study (n ¼ 9). LN cases were then dichotomized into high and low GFR subgroups based on the recommended GFR cutoff value of 60 ml/min/1.73 m 2 , which identifies subjects with clinically significant renal insufficiency. 48 All GFR values were calculated using the Modification of Diet in Renal Disease Study Group (MDRD) formula. 49 SLE patients without LN were used as controls.
Sample preparation DNA templates for polymerase chain reaction (PCR)-based genotyping were prepared from buccal cell brushings as described previously. 50 The Atg M235T polymorphism, which corresponds to the T704C single-nucleotide polymorphism (SNP), was assayed by a primer extension method using the ABI Prism SNaPshot Multiplex System kit (PE Applied Biosystems) and the ABI 3700 DNA Analyzer. The PCR primers were: forward, 5
DNA marker analysis
0 -ATCTCAGCTACACATTGGA TACTAAGTCC-3 0 , and reverse, 5 0 -CAC GCT CTC TGG ACT TCA CAG A-3 0 , and the primer used for the extension reaction was GAA GAC TGG CTG CTC CCT GA. Alleles were determined using the GeneScan v3.5 and Genotyper v3.6 software packages.
The C-532T SNP was assayed by direct PCR sequencing using a 3700 DNA sequence analyzer. The PCR primers were: forward, 5 0 -TCA ATG CCT GCA TCC TGA AG-3 0 and reverse, 5 0 -GA GAG TCT TGC TTA GGC AAC AC-3 0 . The forward primer was used as a sequencing primer. Briefly, PCR amplicons were treated with ExoSAP-IT (USB) to remove additional primers and nucleotides and the sequencing reaction performed using ABI's BigDye Terminator Cycle Sequencing v.2.0. Sequencing data was analyzed using phred v.0.980904.e, phrap v.0.990319 and Consed v.9.0 on a Linux workstation. After computation, the individual traces were examined at the polymorphic base to determine the genotype.
Statistical methods
Demographic, clinical, allele and genotype frequency comparisons in our study groups were examined using w 2 analysis for categorical variables and analysis of variance (ANOVA) for continuous variables. We used logistic regression methods for our dichotomous outcomes (LN and low vs high GFR) to adjust for baseline differences in age at diagnosis and disease duration (from the time of SLE diagnosis) in the LN cases and SLE controls. For GFR as a continuous outcome, we used linear regression methods to adjust for potential confounders, including age at the time of GFR measurement, gender, disease duration and ever use of cytotoxic treatment for LN (treatment with cyclophosphamide, azathioprine or chlorambucil for 46 months). All univariate and multivariate analyses were performed using SPSS version 11.5 (Chicago, IL, USA).
The HWE equation was used to calculate the expected genotype frequencies, which were compared to the observed genotype frequencies by the Pearson w 2 test. Pairwise LD values were calculated using Lewontin's D 0 coefficient. HWE and LD calculations were performed using the Innate Immunity PGA, NHLBI Program for Genomic Applications Software (http://innateimmunity.net).
